The Log
Archive
498 stories, newest first.
July 2026
- Jul 31Technology & Innovation
Eli Lilly Just Paid $3.8 Billion to Bet That Depression's Next Blockbuster Looks Like DMT
Eli Lilly's up-to-$3.8 billion acquisition of AtaiBeckley, weeks after FDA finalized psychedelic clinical trial guidance, signals mainstream pharma is done waiting on the sidelines of psychedelic medicine.
- Jul 31Policy & Funding
The Medicaid Work-Requirement Rule Takes Effect Today. Its Recovery Exemption Has an Expiration Date Built In.
CMS's new Medicaid work-requirement rule is effective today. People in active SUD treatment are exempt — but the exemption disappears after five years in recovery, right when documentation habits have gone slack.
- Jul 31Policy & Funding
DEA Wants to Schedule Concentrated 7-OH Kratom Like Heroin. The Comment Window Closes Today.
HHS's public comment period on DEA's plan to temporarily Schedule I concentrated 7-OH kratom compounds closes today. The rule is narrower than the headlines — here's exactly what it does and doesn't touch.
- Jul 31Science & Medicine
The Ozempic-for-Drinking Trial Just Published Real Numbers. The Headline Effect Missed Its Own Primary Target.
A Phase 2 trial of oral semaglutide for alcohol use disorder found real reductions in heavy drinking days and craving — but missed its own pre-registered primary endpoint. Here's what that gap means, and why the VA is running the next version now.
- Jul 31Lived Experience & Community
Cocaine Got $300 More Expensive an Ounce. Nobody's Demand Went Anywhere — It Went Shopping.
DEA agents in Palm Beach County say they've never seen this much meth. The reason isn't a new addiction — it's a $300-an-ounce price gap with cocaine. What the switch reveals about how dependency actually works.
- Jul 31Treatment & Recovery
Kentucky's Largest Treatment Company Called It Recovery. Its Own Workers Called It Warehousing.
Addiction Recovery Care, once Kentucky's largest treatment provider, agreed to pay $16.2 million over Medicaid fraud. The whistleblowers were peer support specialists who'd also been clients. Here's what the paper trail says happened in the room.
- Jul 30The Crisis, By the Numbers
In Phoenix, July Doesn't Just Feel Deadlier for Meth Use. The Numbers Say It Actually Is.
Maricopa County's deadliest overdose month is consistently July, driven by methamphetamine's effect on the body's ability to regulate heat. Here's the mechanism and what actually helps.
- Jul 30The Crisis, By the Numbers
More Americans Now Smoke Weed Every Day Than Drink Every Day. That's Not the Same as a Win.
2025 NSDUH data shows 21.4 million Americans use cannabis daily or near-daily, more than daily drinkers or daily cigarette smokers, for the first time on record.
- Jul 30Arizona Watch
Arizona's Opioid Settlement Money Went to Prison Healthcare. Nobody Wrote Down Why.
Arizona's Auditor General found the state's prison system spent $50.9M in opioid settlement funds without documenting it met settlement terms, putting over $1B in future payments at risk.
- Jul 30Harm Reduction
Naloxone Still Reverses Fentanyl. It Doesn't Touch What's Being Cut Into It Now.
Nitazenes (up to 40x fentanyl's strength) have been confirmed in 48 of 50 states, and a veterinary sedative called medetomidine is spreading through the fentanyl supply. Naloxone doesn't fully reverse either one. Here's what actually changes for harm reduction.
- Jul 30Lived Experience & Community
Peer Support Workers Are Recovery's Best Technology. Their Employers Still Manage Them Like a Risk.
A new qualitative study of 36 peer and clinical workers in Australia's addiction and mental health services finds that lived experience is the credential clients trust most — and the one workplaces are least equipped to support.
- Jul 29Lived Experience & Community
Nobody Warns You That Year Six of Recovery Has Its Own Crisis. It Just Looks Nothing Like Year One's.
Long-term recovery brings a distinct set of psychological challenges — identity, purpose, relationships — that early-recovery programs rarely prepare people for.
- Jul 29Science & Medicine
45 Million Americans Have a Substance Use Disorder Right Now. The Government's Own Survey Says So — and Says Most Won't Get Treated.
SAMHSA's 2025 NSDUH shows 45 million Americans met SUD criteria in the past year — 15.3% of everyone 12 and older. Here's what the numbers actually say.
- Jul 29The Crisis, By the Numbers
A Cocaine Batch Laced With Fentanyl Just Killed Someone on the Wisconsin-Michigan Border. It Won't Stay There.
A cocaine batch tied to overnight overdoses and one death on the Wisconsin-Michigan border is contaminated with fentanyl — part of a national pattern that's quadrupled cocaine-involved deaths since 2015.
- Jul 29Harm Reduction
Xylazine Was the Adulterant Everyone Learned to Test For. Medetomidine Is 300 Times Stronger, and the Government Just Defunded the Strips That Catch It
Medetomidine, a veterinary sedative up to 300 times more potent than xylazine, is displacing tranq in the fentanyl supply. Here's the science, the scheduling fight, and why test strips matter more than ever.
- Jul 29Arizona Watch
America's Overdose Deaths Are Finally Falling. Arizona's Are Climbing — and Two Federal Rules Land This Week That Make It Worse
Arizona's overdose deaths rose to roughly 2,988 in 2025 while the national count fell 13%. This week, a CMS Medicaid rule and a SAMHSA funding restriction both narrow the safety net further.
- Jul 28Harm Reduction
Substance Spotlight: Inhalants Are the Overdose Crisis Nobody Is Watching, and It's Getting Younger
2024 NSDUH data shows 3.2 million Americans used inhalants in the past year, with teen rates far outpacing adults. A wave of 2026 state legislation targets flavored nitrous oxide products like Galaxy Gas.
- Jul 28Policy & Funding
The Cannabis Rescheduling Hearing Ended. Only One Side Got to Argue.
DEA's rescheduling hearing on moving marijuana to Schedule III concluded July 15, 2026 without a promised livestream; only formal opponents were credentialed as hearing parties. Post-hearing briefs are due August 17.
- Jul 28Lived Experience & Community
Your Insurance Company Doesn't Think of Itself as Part of Your Recovery Plan. It Is.
A Yale addiction-medicine fellow's STAT essay argues insurance disruption functions as a clinical relapse trigger, not just paperwork — grounded in one patient's premium jump from $40 to $138 a month.
- Jul 28Harm Reduction
The Drug That's Replacing Xylazine Is Already Winning, and Your Test Strip Can't See It
Medetomidine, a veterinary sedative far more potent than xylazine, has displaced xylazine in Philadelphia's drug supply in under two years — and standard test strips don't detect it.
- Jul 28Harm Reduction
A Thousand People Watched Someone Overdose. Peers With Naloxone Saved 83 Percent of Them.
A new prospective study across 22 UK and Swedish sites found 83% of witnessed opioid overdoses were reversed with peer-administered take-home naloxone — real-world confirmation of an intervention now facing U.S. funding cuts.
- Jul 28Policy & Funding
Washington Told Treatment Programs What They Can't Say to Get Federal Money. The Deadline Was Yesterday.
SAMHSA's $281 million grant cycle closed July 27, 2026 with language barring applicants from proposing harm reduction. A JAMA Network Open model projects up to 39,600 additional deaths from the related defunding of syringe services.
- Jul 27Science & Medicine
Nicotine Pouches Didn't Slip Past Public Health. They Got Rebranded as Self-Optimization
Nicotine pouch shipments grew 37% in a year almost entirely outside the frame most youth-prevention conversations are still having. Here's how gym-bro TikTok culture, not tobacco advertising, built that growth.
- Jul 27Lived Experience & Community
The Flatness in Month Two Isn't You Failing at Sobriety. It's Your Brain Trying to Refill Itself.
Why the urge to use again in months one through three of meth recovery is a documented dopamine-depletion state, not weakness — and what the science says about when it lifts.